{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis+%28cyclosporine+ophthalmic+emulsion%29+0.05%25&page=2",
    "query": {
      "intervention": "Restasis (cyclosporine ophthalmic emulsion) 0.05%",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis+%28cyclosporine+ophthalmic+emulsion%29+0.05%25&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis+%28cyclosporine+ophthalmic+emulsion%29+0.05%25&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T01:58:01.343Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02653196",
      "title": "A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroepithelial Tumor",
        "Solid Tumor",
        "Allogeneic Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Keratinocyte Growth Factor",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-09",
      "completion_date": "2017-08",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653196"
    },
    {
      "nct_id": "NCT01319773",
      "title": "Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "cyclosporine ophthalmic emulsion Formulation A",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine ophthalmic emulsion Formulation B",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2010-11",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01319773"
    },
    {
      "nct_id": "NCT00983645",
      "title": "A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Prograf",
          "type": "DRUG"
        },
        {
          "name": "Neoral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2004-10",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983645"
    },
    {
      "nct_id": "NCT05322148",
      "title": "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Research Insight LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2022-06-03",
      "completion_date": "2022-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 3,
      "location_summary": "Hemet, California • Laguna Hills, California • Brecksville, Ohio",
      "locations": [
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Brecksville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05322148"
    },
    {
      "nct_id": "NCT00827255",
      "title": "Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Cyclosporine Ophthalmic Emulsion 0.05%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2009-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827255"
    },
    {
      "nct_id": "NCT00739349",
      "title": "NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "NOVA22007 ''Cyclosporine''",
          "type": "DRUG"
        },
        {
          "name": "vehicle/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen SAS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2008-08",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Lewiston, Maine",
      "locations": [
        {
          "city": "Lewiston",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00739349"
    },
    {
      "nct_id": "NCT00157014",
      "title": "Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Diseases",
        "Heart Transplantation"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 111,
      "start_date": "2004-05-10",
      "completion_date": "2008-07-18",
      "has_results": true,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00157014"
    },
    {
      "nct_id": "NCT00987467",
      "title": "Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atopic Keratoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "Cyclosporin 0.05% ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-08",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00987467"
    },
    {
      "nct_id": "NCT04735510",
      "title": "Novel Use of Restasis and PROSE Devices",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Surface Disease"
      ],
      "interventions": [
        {
          "name": "cyclosporine ophthalmic emulsion 0.05%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Sight",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-05",
      "completion_date": "2021-09",
      "has_results": false,
      "last_update_posted_date": "2023-04-19",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Needham, Massachusetts",
      "locations": [
        {
          "city": "Needham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04735510"
    },
    {
      "nct_id": "NCT00553735",
      "title": "The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Cyclosporine A 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Arificial Tear",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2007-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-10-12T01:58:01.343Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00553735"
    }
  ]
}